The largest European-wide observational study on the treatment of primary and metastatic liver tumours with SIR-Spheres microspheres (Sirtex) will present its data on safety and overall survival from its 1,027-patient cohort for the first time at the virtual 2020 meeting of the Cardiovascular and Interventional Radiological Society of Europe (12–15 September).
The study, initiated by CIRSE, collected data on the clinical application of selective internal radiation therapy (SIRT), also known as radioembolization. The data will be presented virtually during a live hot topic symposium: “Research in IR: First results from CIRSE’s observational studies (HTS 1801, Monday 14 September, 14:30–15:30 CEST).
Thomas Helmberger (München Klinik Bogenhausen, Munich, Germany), speaking on behalf of CIRSE as the chairperson of the CIRT Steering Committee, states: “I am extremely proud of all the hard work that my colleagues have put into this study over the last six years. Its success is due to their continuous efforts, and I am very excited to present this data during the upcoming CIRSE 2020 Summit.”